Clinical Trials in Harbin, Harbin
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 1
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Primary Membranous Nephropathy
Everest Medicines (China) Co.,Ltd.30 enrolled19 locationsNCT05800873